

1 **Title:**

2 Immediate effects of a novel lumbar support device on pain modulation and core muscle function  
3 among patients with chronic non-specific low back pain: A randomized controlled trial

4 **Running title:**

5 Immediate effects of a novel lumbar support device

6 **Abstract:**

7 **Background.** A novel lumbar support device to be used by people with chronic nonspecific low  
8 back pain (CNLBP) was designed, developed and tested in this trial. The study investigated the  
9 immediate effects of the novel lumbar support device on pain modulation and core muscle function  
10 in comparison to the traditional lumbar support among people with CNLBP.

11 **Methods.** This study was a single-blinded, repeated measures, randomized controlled trial with  
12 four parallel groups design. A total of 80 patients with CNLBP were randomly allocated using  
13 stratified block randomization by pain severity to one of the four groups: traditional lumbar support  
14 (TLS) as a control group (N = 20), novel lumbar support with hot pack (NLSD + HP) (N = 20),  
15 novel lumbar support with biofeedback device (NLSD + BO) (N = 20), and finally the novel  
16 lumbar support with an in-built hot pack and biofeedback device (NLSD + HP with BO) as an  
17 experimental intervention group (N = 20). Pain intensity (PI), tissue blood flow (TBF), cold pain  
18 threshold (CPT), hot pain threshold (HPT), thickness of transversus abdominis muscle (TrA), and  
19 lumbopelvic stability (LPS) were assessed at baseline and immediately post-intervention by a  
20 blinded assessor. A two-way repeated-measures ANOVA with post-hoc analysis was used to  
21 analyze the data.

22 **Results.** All 80 participants across the 4 groups had similar outcome measures at baseline ( $p > 0.05$ ).  
23 Among the participants in the NLSD + HP with BO (Group 4), a significant interaction was noticed

24 in all of the primary outcomes including PI ( $p < 0.001$ ), TBF ( $p < 0.001$ ), CPT ( $p < 0.001$ ), HPT  
25 ( $p < 0.001$ ), PPT ( $p < 0.001$ ), TrA thickness ( $p < 0.001$ ) and as well as on the secondary outcome  
26 lumbopelvic stability ( $p < 0.001$ ). Post hoc analysis showed that the results from the NLSD + HP  
27 with BO (Group 4) was superior than the TLS group in all of the primary and secondary outcomes  
28 ( $p < 0.05$ ).

29 **Conclusion.** The immediate effects of the NLSD + HP with BO demonstrated potential beneficial  
30 outcomes on PI, PPT, CPT, HPT, TrA and LPS in comparison to TLS among participants with  
31 CNLBP. Further clinical trial evaluating the long-term clinical effects of the novel lumbar support  
32 device is needed to understand the overall benefits of the device and its usefulness for people with  
33 CNLBP.

34 **Level of evidence:** 2b

35 **Keywords:** Back pain; core muscles; hot pack; lumbar support; rehabilitation.

36

37

38

39

40

41

42

43

44

45

46

## 47 **Background**

48           Low back pain (LBP) is a common musculoskeletal problem which leads to functional  
49 limitations and disability <sup>1</sup>. Chronic low back pain (CLBP) is reported to affect the physical and  
50 mental health of the individuals <sup>2</sup>. While there are several treatment strategies such as medication,  
51 surgery, acupuncture, manual therapy, physical exercises, heat and cold therapy reported for  
52 management of CLBP <sup>3,4</sup>, lumbar support (LS) is suggested as one among them to prevent and  
53 treat LBP <sup>5,6</sup>. The mechanisms that have been proposed for the effectiveness of LS in the  
54 management of LBP are increase in intra-abdominal pressure, decrease in spinal load, increase in  
55 trunk stiffness, maintenance of correct posture and increase in proprioception are some of the  
56 proposed mechanisms behind how LS may help people with CLBP <sup>6,7</sup>. LS is reported to reduce  
57 the symptom of LBP and increase the patient's confidence to perform physical activities <sup>8</sup>. Also,  
58 patients with LBP felt safer and more stable during physical activity when wearing lumbar support  
59 <sup>9</sup>. Patients with CLBP also reported decreased pain and improved functional ability when wearing  
60 LS <sup>5,10</sup>. However, there is a concern that using a LS for a longer period may lead to a decrease in  
61 the abdominal and back muscle activity and trunk muscle weakness <sup>9,11</sup>. Therefore, LS seems to  
62 be effective when incorporating with the usual care of LBP management <sup>12</sup>.

63           While some individuals may choose to use traditional lumbar support (TLS) to prevent or  
64 manage low back pain, the TLS only provides a passive support to the lumbosacral region. Thus,  
65 the passive therapeutic support provided by the TLS had raised some concerns that using TLS for  
66 a longer period of time might lead to a decrease in the abdominal and back muscle activity and  
67 reduced trunk muscle weakness <sup>9,11</sup>. A Cochrane systematic review from the neck and back group  
68 indicates that the TLS is not more effective than no intervention in preventing or treating CLBP <sup>6</sup>.  
69 Perhaps, the TLS might be more effective when incorporating with exercises and usual care of

70 CLBP management <sup>12</sup>. Also, it could be possible that the current design of the TLS was not  
71 effective enough and a reconfiguration of the design of the lumbar support with additional  
72 therapeutic features was required.

73 Therefore, a novel lumbar support device (NLSD) was designed and developed with  
74 additional therapeutic features and the current study was to report the investigation of the NLSD  
75 among individuals with CLBP. In addition to giving support to the lumbosacral region, the NLSD  
76 was designed with additional therapeutic features which includes a biofeedback mechanism to  
77 activate core muscles and with a provision to produce superficial moist heat therapy to back  
78 muscles. Thus, the patients could use the core muscle activation feedback in the NLSD to actively  
79 exercise their core muscles and as well as to apply a superficial heat therapy to the back muscles.  
80 Therefore, the main aim of the study was to investigate the immediate effects of NLSD in  
81 comparison to the TLS on pain modulation and core muscle function among patients with CLBP.  
82 The study hypothesis was that the NLSD would be superior to the TLS in improving pain  
83 modulation and core muscle function among people with CLBP.

#### 84 **Materials and Methods**

85 The current study was a single-blinded, repeated measures, randomized controlled trial  
86 with four parallel groups. The study protocol was registered in the randomized control trial registry  
87 (TCTR20190905002) and approved by the institutional ethical committee according to the  
88 standards of the Declaration of Helsinki (AMSEC60X028). All participants were informed about  
89 the study and signed a written informed consent prior to their participation in the study. All authors  
90 have followed the international ethical principles and the ethical standards of the Muscle,  
91 Ligaments and Tendons Journal <sup>13</sup>.

92

93 **Randomization and allocation**

94 Participants were randomly allocated (1:1:1:1 ratio) to one of four intervention groups 1)  
95 Group 1- TLS group, 2) Group 2 - NLS with hot pack feature (NLS + HP), 3) Group 3 - NLS with  
96 biofeedback core muscle activator (NLS + BO) and 4) Group 4 - NLSD which had both the features  
97 of hot pack and biofeedback core muscle activator (NLSD + HP with BO). The randomization was  
98 stratified by severity of back pain (i.e., pain intensity). An internet randomized scheme generator  
99 which generated block randomization with a random sequence of permuted blocks of 8 was used  
100 for allocating the participants for the intervention groups. An independent research staff undertook  
101 randomization and allocation of the participants in the trial.


102 **Allocation concealment**

103 The group assignment number was written on a piece of paper and placed in an opaque  
104 envelope and sealed. The member of the staff who conducted these processes did not have any  
105 roles in data collection or intervention assignment. The opaque sealed envelopes were opened after  
106 completion of baseline assessment.

107 **Participants**

108 The study was conducted in a neuromuscular and pain research unit at the physiotherapy  
109 department in a university institutional setting during January and December 2019. A total of 80  
110 participants both males and females aged between 20 – 55 years with non-specific chronic low  
111 back pain (NSCLBP) were recruited into the study. The study details and participant recruitment  
112 procedures were advertised through community centers and Facebook, and advertisement posters  
113 were placed in the hospitals, physical therapy clinics, and university campus to facilitate  
114 recruitment. The inclusion criteria were: 1) pain in the area between 12th rib to gluteal fold for  
115 more than three months, 2) body mass index (BMI) between 18.5 - 30 kg/m<sup>2</sup>, and 3) willing to

116 participate in the study voluntarily. Participants excluded were those that had any of the following:  
 117 1) referred pain or numbness at lower limbs, 2) impaired sensation at the body and lower limbs, 3)  
 118 history of past surgery of spine or lower extremities, 4) history of injury from an accident in the  
 119 previous three months, 5) structural deformities of the spine, 6) pregnancy, 7) specific spinal  
 120 disorders or nerve root compression, 8) inflammation or infection at spine and back, 9) severe  
 121 medical conditions such as cardiovascular disease, renal failure, hypertension, diabetes, and 10)  
 122 those who received any pain-relieving medication in the previous three months. **Figure 1** shows  
 123 the flow of the study recruitment.



124  
 125 **Figure 1** CONSORT flow diagram of participant recruitment and allocation in the study  
 126

127 **Interventions**

128 A qualified therapist experienced in the field of musculoskeletal physiotherapy provided  
129 the intervention. Blinding of participants was not possible due to the nature of the interventions.  
130 Participants were advised to inform if they would experience any discomfort during the  
131 interventions and were allowed to leave the experiment if the participants requested to leave the  
132 study due to any personal reasons or reported worsening of symptoms. Any adverse events or any  
133 incidents of reported discomfort during the intervention period were recorded.

134 **Group 1 – Traditional lumbar support (TLS) as Control group**

135 Participants received a TLS (Model: LS, Manufacturer: VR Support Limited, Thailand)  
136 which fitted to the body size of each participant. Two sizes of lumbar support (i.e., medium and  
137 large) were used for the interventions generally according to the hip sizes of the participants. The  
138 participants were taught to wear lumbar support around the lumbopelvic region (the upper edge of  
139 lumbar support is just below the 12th ribs) firmly. The participants had worn a traditional lumbar  
140 support and were asked to complete 4 rounds of standing for 4 minutes and had a rest by sitting  
141 for 1 minute. The standing and sitting positions were chosen to represent the functional activities  
142 and common gestures of working in daily life. As part of the intervention to measure the immediate  
143 effects of the lumbar support, the participants were instructed to wear the TLS for 20 minutes.

144 **Group 2 – Novel lumbar support device with in-built hot pack (NLSD + HP)**

145 The selection of the sizes of the lumbar support, application technique and the  
146 familiarization procedure were performed similar to the control group. However, the NLSD + HP  
147 used in the Group 2 consisted of an additional feature to provide superficial heat therapy through  
148 a hot pack feature designed in the lumbar support. While the participants wore the lumbar support,

149 the participants received superficial heat therapy to back muscles from the NLSD + H for 20  
150 minutes.

151 **Group 3 – Novel lumbar support device with in-built biofeedback device (NLSD + BO)**

152 The familiarization protocol and application techniques were similar to group 1 and 2. The  
153 NLSD + BO was designed with an additional feature consisting of a mechanism that provided a  
154 visual biofeedback whenever the participants successfully engaged the core muscles. The validity  
155 and reliability of the feedback sensor to facilitate the core muscles activation was tested and  
156 established prior to the intervention <sup>14</sup>. The feedback sensor was a biofeedback device that was  
157 developed using a pressure sensor. The feedback sensor was designed with a mechanism to give  
158 both audio and visual biofeedback to the participants every time when they contracted the core  
159 muscles during ADIM. The participants could select whether they would like to receive either an  
160 audio biofeedback through a beeping sound or a visual feedback through a blinking light while  
161 they tried to contract the core muscles. With the feedback sensor fixed within the lumbar support,  
162 the participants were taught to perform core muscle activation by doing an abdominal drawing-in  
163 maneuver (ADIM) and the biofeedback device facilitated the maneuver by providing a visual and  
164 auditory feedback to the participants to engage with subsequent core muscle activation. While  
165 wearing the lumbar support, the participants were instructed to perform ADIM in the standing  
166 position and hold it for 10 seconds/time, 20 times/set 4 sets and to rest for 1 minute by sitting in  
167 between the sets. The whole session lasted for 20 minutes.

168 **Group 4 – Novel lumbar support with in-built hot pack & biofeedback (NLSD + HP with**  
169 **BO)**

170 The application techniques and familiarization procedures were performed similar to the  
171 above groups. The NLSD + HP with BO was designed with two additional features which included



172 a mechanism to produce superficial heat therapy and had a feature to provide a visual feedback to  
173 participants to exercise the core muscles. While wearing the lumbar support, the participants  
174 superficial heat therapy to back muscles and also performed ADIM holding it for 10 seconds/time,  
175 20 times/set, 4 sets with 1-minute rest by sitting in between the sets. The duration of the whole  
176 intervention was 20 minutes.

### 177 **Outcome measures**

178 An independent assessor measured all the outcomes of the trial. The outcome measures  
179 were measured at baseline and immediately after 20 minutes of the intervention in each group. An  
180 intra-rater reliability was established prior to the enrollment of participants and data collection,  
181 with an acceptable value of agreement greater than 80% and intraclass correlation coefficients  
182 (ICCs) ranged from 0.87 – 0.99 for all measures. Pain modulation was measured as one of the  
183 primary outcomes through evaluating changes in the pain intensity (PI), pressure pain threshold  
184 and thermal pain threshold. In addition, thickness of transversus abdominis muscle and the tissue  
185 blood flow were measured as additional primary outcomes. Lumbopelvic stability test was used to  
186 evaluate the stability of the lumbopelvic region as a secondary outcome.


187 The procedure for measuring pain modulation was conducted as per previously established  
188 protocol <sup>15,16</sup>. Visual analog scale (VAS) was used to assess pain intensity. The participants rated  
189 their pain intensity (PI) on a horizontal line in a 100 millimeters length scale which says “no pain”  
190 on the left hand and “pain as bad as possible” on the right hand of the scale <sup>17</sup>. Pressure pain  
191 threshold (PPT) was assessed by using pressure algometer (Somedic Production, Algometer type  
192 II, Sweden). Pressure was applied perpendicularly to the skin at constant speed of 40 kPa/s. The  
193 participants pressed a button to inform the sensation changing from the pressure to pain by pressing  
194 a button. PPT was randomly measured over the standard fixed point (facet joints) of L4 – L5 on

195 both sides. PPT was assessed 3 times with 30-sec resting between trials and mean of the 3 trials  
196 will be used for analysis <sup>18</sup>. The thermal pain threshold was measured by a Thermal Sensory  
197 Analyzer (Medoc Ltd., Neuro Sensory Analyzer Model TSA-II, Israel) for cold pain threshold  
198 (CPT) and heat pain threshold (HPT). A 5-cm<sup>2</sup> thermode was directly applied to the skin over the  
199 L4-5 interspinous space. The initial temperature was set at 32° C with the rate change 1 degree  
200 Celsius/ second for heat pain and 2 degrees Celsius/ second for cold pain <sup>18</sup>. The cut off temperature  
201 was set at 0° C for cold pain threshold and 50° C for heat pain threshold for preventing any possible  
202 tissue damage. The participants were instructed to press the button when they felt the sensation  
203 changing from heat or cold to pain. Thermal pain threshold was assessed 3 times and mean of the  
204 3 trials was used for analysis.

205 Real-time ultrasound imaging was used to evaluate the muscle function of the transversus  
206 abdominis muscle (TrA) which is an important core stabilizing muscle. The muscle function of  
207 the TrA was measured as per an established protocol <sup>19</sup>. An ultrasound scanner in B-mode with 5  
208 MHz with curvilinear transducer was used to assess the muscle thickness of TrA (**figure 2**). The  
209 participants were positioned in crooked lying with a pillow under their head and knees. The  
210 transducer was placed at a point 2.5 cm in the anteromedial region in the midpoint between lower  
211 rib and iliac crest on midaxillary line in transverse plane and the image was collected at the end of  
212 exhalation. Thickness of TrA was randomly measured on both sides and the mean thickness of  
213 three measurements was calculated for analysis.

214 The tissue blood flow (TBF) was measured using a Doppler blood flow meter (Moor  
215 instruments DRT4, UK) as per an established protocol <sup>16</sup>. The participants lied in prone position  
216 with arm by side. The electrode of the Doppler blood flow meter was placed over a standard fixed  
217 point on the tenderest place over the lumbar paravertebral muscle between the first and fifth lumbar

218 vertebral region. The TBF was recorded every minute for a period of 5 minutes and the mean value  
219 was used for analysis. In addition, stability of the lumbopelvic region (LPS) was evaluated as a  
220 secondary outcome measure using the lumbopelvic stability test. With the participant in supine  
221 lying position with knee flexed to 70 degrees, a pressure biofeedback unit was pumped to 40  
222 mmHg and placed under the lumbar spine between the lumbar and sacral region (L2 - S1). The  
223 participants performed a unilateral leg lift in the sagittal plane followed by progressive levels of  
224 seven lumbopelvic stability tests as per the test protocol<sup>16</sup>. The participants were asked to maintain  
225 the pressure within  $40 \pm 4$  mmHg in the pressure biofeedback device while progressing to different  
226 levels of test. The test was stopped when the participants were not able to hold  $40 \pm 2$  mmHg in  
227 the biofeedback device and the test level was noted.



228  
229 **Figure 2.** Ultrasound image of the Transversus abdominis muscle (TrA), Internal oblique (IO) and  
230 External oblique (EO).

### 231 Statistical analysis

232 The sample size was calculated with a G\*power program for a significant alpha level of  
233 0.05 and a power analysis of 0.8 with an estimated effect size of 0.54. The collected data were  
234 analyzed for normal distribution using the Kolmogorov Smirnov test. A two-way repeated-  
235 measures ANOVA (4 conditions x 2 times) was used to consider the interaction effects and the

236 main effects of the experimental conditions and time. A post-hoc analysis was conducted and the  
237 level of significance was set as ( $p < 0.05$ ). The percentage change in all variables was measured by  
238 calculating the difference between pre- and post-intervention changes divided by 100. The  
239 estimated effect size was calculated using partial eta square ( $\eta_p^2$ ). An effect size was interpreted  
240 as following: small effect (0.2), medium effect (0.5), and large effect (0.8) <sup>20</sup>.


## 241 **Results**

242 A total of 80 participants (33 males and 47 females) with CNSLBP participated in this  
243 study with a mean age ( $41.3 \pm 9.1$ ) (years) and mean BMI score ( $23.5 \pm 13.2$ ) ( $\text{kg}/\text{m}^2$ ). The mean  
244 onset of low back pain among the participants was  $35.9 \pm 38.8$  months and they reported Oswestry  
245 Disability Index mean score of  $18.7 \pm 10.6$  (%). The characteristics of the participants allocated to  
246 the four groups were shown in the **Table I**. There were no significant differences between the  
247 study groups in terms of gender, age, body mass index (BMI), the onset of LBP, and disability  
248 score at the baseline.

249 There were no significant differences in any of the variables at the baseline between the  
250 study groups ( $p > 0.1$ ). **Table II** shows the two-way repeated measure ANOVA results on the  
251 interaction effect between groups and time in all variables ( $p < 0.05$ ). The participants in the TLS  
252 (Group 1) showed significant interaction only in the PI ( $p < 0.001$ ), and PPT ( $p < 0.01$ ) in  
253 comparison to baseline measures. The results showed that the participants in the NLSD + HP  
254 (Group 2) showed significant interaction in PI ( $p < 0.001$ ), TBF ( $p < 0.001$ ), CPT ( $p < 0.001$ ) and  
255 PPT ( $p < 0.001$ ), however no interaction was noticed in the TrA thickness ( $p > 0.05$ ) and stability  
256 of the lumbopelvic region ( $p > 0.05$ ). In comparison to the baseline values, the results showed that  
257 the participants in the NLSD + BO (Group 3) had significant interaction in PI ( $p < 0.001$ ), TBF ( $p$   
258  $< 0.05$ ), CPT ( $p < 0.05$ ), PPT ( $p < 0.001$ ), TrA thickness ( $p < 0.001$ ), lumbopelvic stability ( $p <$

259 0.001) except HPT ( $p > 0.05$ ). Finally in the NLSD + HP with BO (Group 4), a significant  
 260 interaction was noticed in all of the primary outcomes including PI ( $p < 0.001$ ), TBF ( $p < 0.001$ ),  
 261 CPT ( $p < 0.001$ ), HPT ( $p < 0.001$ ), PPT ( $p < 0.001$ ), TrA thickness ( $p < 0.001$ ) and as well as on  
 262 the secondary outcome lumbopelvic stability ( $p < 0.001$ ). Post hoc analysis showed that the results  
 263 from the NLSD + HP with BO (Group 4) was superior than the TLS group in all of the primary  
 264 and secondary outcomes. Also, the post hoc analysis showed that the NLSD + HP with BO (Group  
 265 4) results were superior to the NLSD + HP (Group 2) in the outcomes such as HPT, TrA thickness  
 266 and stability of lumbopelvic region ( $p < 0.05$ ) and as well as superior to the NLSD + BO (Group  
 267 3) in all of the primary ( $p < 0.05$ ) and secondary outcomes ( $p < 0.05$ ) except TrA thickness ( $p > 0.05$ ).  
 268 **Figure 3** showed the percentage change for all outcome measures.

269  
270



271

272 **Figure 3.** The percentage change for the primary and secondary outcomes. Traditional lumbar  
 273 support (TLS): filled column, novel lumbar support with hot pack (NLSD + HP): striped column,

274 novel lumbar support with biofeedback device (NLSD + BO): dotted column, novel lumbar  
275 support with hot pack and biofeedback device (NLSD + HP with BO: twill column. PI: pain  
276 intensity, TBF: tissue blood flow, PPT: pressure pain threshold, CPT: cold pain threshold, HPT:  
277 heat pain threshold, TrA: thickness of transversus abdominis muscle, LPST: lumbopelvic stability  
278 test.

## 279 **Discussion**

280 The current study investigated the immediate effects of NLSD + HP with BO on PI, TBF,  
281 PPT, HPT, CPT, TrA thickness and LPS in comparison to TLS among patients with CNLBP. The  
282 results of the study supported the hypothesis that the NLSD + HP with BO in comparison to TLS  
283 had superior therapeutic effects in all the primary outcomes (PI, TBF, PPT, HPT, CPT, TrA  
284 thickness) and secondary outcome (LSP) among CNLBP patients. TLS has some significant  
285 challenges in terms of application to clinical practice for management of CNLBP. Current state of  
286 scientific evidence questions the effectiveness of the TLS and raises concern on the use of lumbar  
287 support for the prevention and management of low back pain <sup>6</sup>. Also, prolonged use of TLS is  
288 reported to cause trunk muscle weakness and decreased trunk muscle activity <sup>9,11</sup>. While there are  
289 different brands of lumbar support is available, they all were designed to provide a passive support  
290 to the lumbar region. Therefore, it was decided to redesign a lumbar support with built in additional  
291 features such as superficial heat therapy and a biofeedback to exercise the core muscles. Thus, two  
292 more study groups NLSD + HP (Group 2) and NLSD + BO (Group 3) were added as additional  
293 comparative groups in this trial to study and evaluate the effects of having the superficial heat  
294 therapy and biofeedback mechanism in the lumbar support. Finally, NLSD + HP with BO (Group  
295 4) was added and studied as the experimental intervention group to evaluate the combined effects  
296 of adding superficial heat therapy and biofeedback mechanism in the lumbar support. Prior to the

297 initiation of the current trial, the design and function of the novel lumbar support device was tested  
298 and proven to have reliable and valid features<sup>14</sup>. Thus, the results of the study validated the design  
299 features of the NLSD + HP with BO and supported that the inclusion of additional novel features  
300 in the device such as superficial heat therapy with a biofeedback mechanism to engage core  
301 muscles produced desirable benefits to the CNLBP patients.

302         The results suggested that wearing the NLSD + HP with BO for 20 minutes induced an  
303 immediate physiological change as observed by an increase in the TBF lumbar region. Increase in  
304 TBF is suggested to promote the healing process by supplying more oxygen and nutrients to the  
305 site of injury and removes the irritant substances<sup>21</sup>. Therefore, the magnitude of change in the TBF  
306 reported in the study might have positive implications for CNLBP patients. The increase in TBF  
307 was found to be higher in the group which had NLSD + HP with BO and the effect was clinically  
308 significant with a larger effect size (partial eta-squared ( $\eta_p^2$ ) - 0.7) when compared to the other  
309 three groups. In clinical practice, quantitative sensory testing (QST) is used to evaluate  
310 hypersensitivity and hyperalgesia which are associated with long term pain conditions such as  
311 CNLBP<sup>22</sup>. Therefore, QST (PPT, HPT and CPT) was used as a standardized outcome measure  
312 along with PI to evaluate the effects on pain modulation<sup>17,22</sup>. In clinical setting, the practitioners  
313 might be able to understand the effects of an intervention by monitoring improvement in the pain  
314 reported by patients<sup>15</sup>, hence pain modulation was observed as a primary outcome measure  
315 through evaluating QST along with PI. Besides the increase in the TBF, the results showed that  
316 NLSD + HP with BO had immediate effects on pain modulation. The results showed that the  
317 percentage increase of PPT was observed to be higher in the NLSD + HP group (28.92%)  
318 compared to the TLS group (9.51%). As PPT has been suggested to be most predictive of  
319 CNLBP<sup>23</sup>, the clinically meaningful change in PPT among participants who used NLSD + HP with

320 BO may be considered as a useful finding in this study. Besides increasing tolerance of mechanical  
321 pain, CPT and HPT also showed significant positive changes in the NLSD + HP with BO group  
322 where by the CPT decreased by approximately 62.2% and HPT improved by 6%. In addition, the  
323 PI also a clinical meaningful reduction (61.7%) in Group 4 in comparison to other three groups.  
324 Superficial heat therapy results in pain relief, reduced muscle stiffness, and increased flexibility  
325 among LBP patients <sup>24</sup>. The novel lumbar support device was designed to provide superficial heat  
326 therapy to back muscles which could explain the overall superior effects on pain modulation  
327 observed in the NLSD + HP with BO group when compared to the TLS group.

328 Deeper abdominal muscle such as TrA provides stability to the lumbopelvic region. Also,  
329 TrA has been reported to have impairment among people with LBP <sup>25</sup>. Therefore, thickness of the  
330 TrA muscle was evaluated to measure the changes in TrA muscle activity and LPS was evaluated  
331 as a secondary outcome measure in the study. When compared to the TLS group, the participants  
332 in the NLSD + HP with BO group showed a higher increase in both the TrA muscle activity and  
333 LPS with a percentage change of 27.5% and 45% respectively. An evidence suggests that lumbar  
334 support may positively affect trunk motion as it reduces trunk motion for flexion– extension and  
335 lateral bending <sup>7</sup>. However, there is no evidence to suggest that this can increase TrA muscle  
336 activity and LPS. Currently, there are no data from previous literature available to compare the  
337 effects of lumbar support on LPS and TrA thickness. The novel lumbar support device had a design  
338 feature of a biofeedback mechanism to support and assist the participants to exercise the deeper  
339 core muscles. Prior to the current study, the reliability and validity of the biofeedback mechanism  
340 in the novel lumbar support for activation of core muscle (TrA) was established <sup>14</sup>. Perhaps, the  
341 changes observed on LSP and TrA muscle activity might be related to the fact that the participants  
342 in the NLSD + HP with BO group used the biofeedback device and exercised their core muscles



343 while they wear the novel lumbar support. Also, it is possible that the increase in the TrA muscle  
344 activity and LPS might be related with the pain modulation effects reported among the study  
345 participants. Further studies are warranted to understand the underlying mechanism and effects of  
346 the NLSD + HP with BO on trunk stability.

347         This study may have some limitations. First, the study investigated only the immediate  
348 effects of the novel lumbar support device to establish its potential mechanisms of action on pain  
349 modulation and core muscle function. Nevertheless, the study on the immediate effects was  
350 warranted to establish the performance of the novel lumbar support device and as well the findings  
351 of the current study was used as a catalyst to plan and conduct a long-term trial. The NLSD + HP  
352 with BO provided a superficial heat therapy to the back muscles for about 20 minutes which might  
353 have caused changes in the tissue temperature of skin and muscles. As the post study measurements  
354 were conducted immediately after the heat therapy application, the change in the skin temperature  
355 could be a potential confounder to the thermal threshold measurements. However, having the TLS  
356 group as a control group and observing the changes in the thermal threshold among the TLS group  
357 helped to interpret the thermal threshold findings in the study. Several factors such as sleep quality  
358 and patterns, psychosocial factors, pain medications, underlying medical history, caffeine intake,  
359 gender, age and body composition may influence sensory perception and outcomes of sensory  
360 testing. While few factors such as BMI, pain medication, underlying medical conditions were  
361 monitored and controlled in the trial, other factors were not controlled which could be potential  
362 confounders. As the NLSD + HP with BO was considered as an experimental intervention and the  
363 study was designed to test the design features and its effects, the study findings had limited external  
364 validity. However, the design and development of the novel lumbar support device had undergone  
365 strict scientific process of reliability and validity examination to ensure that it is functioning well

366 before the current trial was conducted. In addition, the current trial encompassed a wide range of  
367 outcome measures which were relevant to current clinical practice in low back pain management  
368 and hence, the findings could be relevant to practice. Therefore, future studies evaluating the  
369 effects of the novel lumbar support might need to include these additional variables as important  
370 outcomes among CLBP patients. **Another limitation of the study was that the participants recruited  
371 in this study showed only a minimal pain related disability with the Oswestry score showing <20%  
372 in three of the four groups. Therefore, it was important to acknowledge that the effectiveness of  
373 the new device should be further investigated not only to assess its long-term clinical effects, but  
374 also its usefulness in low back patients presenting moderate and severe disability.** Currently, a  
375 clinical trial is ongoing to determine long-term effects of the NLSD + HP with BO among CNLBP  
376 population and therefore any wider implications and effects of the novel lumbar support need  
377 among CNLBP patient needs to be revisited again.

### 378 **Conclusion**

379 The immediate effects of the novel lumbar support device showed potential beneficial  
380 effects on pain modulation and core muscle function among patients with CNLBP in comparison  
381 to the traditional lumbar support. Further clinical trial evaluating the long-term clinical effects of  
382 the novel lumbar support device is needed to understand the overall benefits of the device and its  
383 usefulness for people with CNLBP.

### 384 **Conflict of interests**

385 No conflict of interests.

386

387

388

389

390 **References**

- 391 1. R. Dimer da Luz, M. da Silva Santos, A. Steffen Evaldt, L. da Silva Matos, R. Boff Daitx,  
392 M. B. Döhnert. Neuromuscular electrical stimulation associated with core stability exercises in  
393 nonspecific postural low back pain: a randomized clinical trial Original Article, 446-456. *Muscles  
394 Ligaments Tendons J.* 2019;9 (3); 446-456.
- 395 2. De Giorgio A., Padulo J., Kuvačić G. Effectiveness of yoga combined with back school  
396 program on anxiety, kinesiophobia and pain in people with non-specific chronic low back pain: a  
397 prospective randomized trial *Muscles Ligaments Tendons J.* 2018;8 (1); 104-112.
- 398 3. Steffens D, Maher C, Pereira L, Stevens M, Oliveira V, Chapple M. Prevention of low back  
399 pain: a systematic review and meta-analysis. *JAMA Intern Med* 2016;176:199–208.
- 400 4. Pengel HM, Maher CG, Refshauge KM. Systematic review of conservative interventions  
401 for subacute low back pain. *Clin Rehabil* 2002;16(8):811-20.
- 402 5. Calmels P, Queneau P, Hamonet C, et al. Effectiveness of a lumbar belt in subacute low  
403 back pain: an open, multicentric, and randomized clinical study. *Spine* 2009;34(3):215-20.
- 404 6. van Duijvenbode I, Jellema P, van Poppel M, van Tulder M. Lumbar supports for  
405 prevention and treatment of low back pain. *Cochrane Database Syst Rev* 2008(2):CD001823.
- 406 7. van Poppel MN, de Looze MP, Koes BW, Smid T, Bouter LM. Mechanisms of action of  
407 lumbar supports: a systematic review. *Spine* 2000;25(16):2103-13.
- 408 8. McNair PJ, Heine PJ. Trunk proprioception: enhancement through lumbar bracing. *Arch  
409 Phys Med Rehabil* 1999;80(1):96-9.

- 410 9. Cholewicki J, McGill KC, Shah KR, Lee AS. The effects of a three-week use of  
411 lumbosacral orthoses on trunk muscle activity and on the muscular response to trunk perturbations.  
412 BMC Musculoskelet Disord 2010;11(1):1-10.
- 413 10. Morrisette DC, Cholewicki J, Patenge WF, Logan S, Seif G, McGowan S. A randomized  
414 clinical trial comparing extensible and inextensible lumbosacral orthoses and standard care alone  
415 in the management of lower back pain. Spine 2014;39(21):1733.
- 416 11. Fayolle-Minon I, Calmels P. Effect of wearing a lumbar orthosis on trunk muscles: study  
417 of the muscle strength after 21 days of use on healthy subjects. Joint Bone Spine 2008;75(1):58-  
418 63.
- 419 12. Dissanguan D, Sitalertpisan P, Joseph L, Paungmali A. Effectiveness of Lumbar Support  
420 in Management of Low Back Pain: A Systematic Review. Online J Health Allied Scs 2018;17(4):3.
- 421 13. Padulo J, Oliva F, Frizziero A, Maffulli N. Muscles, Ligaments and Tendons Journal -  
422 Basic principles and recommendations in clinical and field Science Research: 2016 Update.  
423 Muscles Ligaments Tendons J. 2016;6(1):1-5.
- 424 14. Dissanguan D, Sitalertpisan P, Kiatwattanacharoen S, Joseph LH, Puangmali P, Paungmali  
425 A. Reliability and Validity of the Feedback Sensor for Activating the Transversus Abdominis  
426 Muscle. Open Biomed Eng 2019;13(1):67-73.
- 427 15. Paungmali A, Joseph LH, Sitalertpisan P, Pirunsan U, Uthaikhup S. Lumbopelvic core  
428 stabilization exercise and pain modulation among individuals with chronic nonspecific low back  
429 pain. Pain Pract 2017;17(8):1008-14.
- 430 16. Joseph LH, Hancharoenkul B, Sitalertpisan P, Pirunsan U, Paungmali A. Effects of massage  
431 as a combination therapy with Lumbopelvic stability exercises as compared to standard massage

- 432 therapy in low Back pain: a randomized Cross-over study. *Int J Ther Massage Bodywork*  
433 2018;11(4):16.
- 434 17. Litcher-Kelly L, Martino SA, Broderick JE, Stone AA. A systematic review of measures  
435 used to assess chronic musculoskeletal pain in clinical and randomized controlled clinical trials. *J*  
436 *Pain* 2007;8(12):906-13.
- 437 18. Malmström E-M, Stjerna J, Högestätt ED, Westergren H. Quantitative sensory testing of  
438 temperature thresholds: Possible biomarkers for persistent pain? *J Rehabil Med* 2016;48(1):43-7.
- 439 19. Leonard J, Paungmali A, Sitalertpisan P, Pirunsan U, Uthaikhup S. Changes in Transversus  
440 Abdominis Muscle Thickness after Lumbo-Pelvic Core Stabilization Training among Chronic  
441 Low Back Pain Individuals. *Clin Ter* 2015;166(5):e312-6.
- 442 20. Cohen J. *Statistical power analysis for the behavioural sciences*: London: Academic Press;  
443 1977.
- 444 21. Lehmann JF, Warren CG, Scham SM. Therapeutic heat and cold. *Clin Orthop Relat Res*  
445 1974;99:207-45.
- 446 22. Walk D, Sehgal N, Moeller-Bertram T, et al. Quantitative sensory testing and mapping: a  
447 review of nonautomated quantitative methods for examination of the patient with neuropathic pain.  
448 *Clin J Pain* 2009;25(7):632-40.
- 449 23. Neziri AY, Curatolo M, Limacher A, et al. Ranking of parameters of pain hypersensitivity  
450 according to their discriminative ability in chronic low back pain. *Pain* 2012;153(10):2083-91.
- 451 24. Nadler SF, Steiner DJ, Petty SR, Erasala GN, Hengehold DA, Weingand KW. Overnight  
452 use of continuous low-level heatwrap therapy for relief of low back pain. *Arch Phys Med Rehabil*  
453 2003;84(3):335-42.

454 25. Rackwitz B, de Bie R, Limm H, von Garnier K, Ewert T, Stucki G. Segmental stabilizing  
 455 exercises and low back pain. What is the evidence? A systematic review of randomized controlled  
 456 trials. Clin Rehabil 2006;20(7):553-67.

457  
 458  
 459 **Table I.** Characteristics of the study participants shown as mean  $\pm$  standard deviation (SD) across the four  
 460 groups.

Variables/ Group	TLS (n = 20)	NLSD + HP (n = 20)	NLSD + BO (n = 20)	NLSD + HP with BO (n = 20)	p- valu e
Gender (M/F)	8/12	10/10	6/14	9/11	0.61
Age (years)	40.5 $\pm$ 9.99	41.45 $\pm$ 9.93	40.45 $\pm$ 7.8	43.05 $\pm$ 8.82	0.78
BMI (kg/m <sup>2</sup> )	23.46 $\pm$ 3.96	23.96 $\pm$ 2.86	22.55 $\pm$ 3.33	24.24 $\pm$ 2.75	0.38
Onset of LBP (months)	24.75 $\pm$ 22.87	31.05 $\pm$ 34.72	48.1 $\pm$ 59.53	40.0 $\pm$ 38.42	0.30
ODI score (%)	22.47 $\pm$ 12.09	18.94 $\pm$ 10.73	17.01 $\pm$ 10.16	16.48 $\pm$ 9.69	0.28

461  
 462  
 463  
 464  
 465  
 466

468 **Table II.** Data of all variables and mean difference values are shown as mean (SD).

Outcomes		Groups				Interaction effect	
		TLS (n=20)	NLSD + HP (n=20)	NLSD + BO (n=20)	NLSD + HP with BO (n=20)	p-value	$\eta_p^2$
VAS (mm)	Pre	30.65 (22.74)	36.25 (18.37)	34 (22.49)	33 (18.49)	0.001	0.2
	Post	20.9 <sup>***</sup> (18.36)	17.4 <sup>***</sup> (13.39)	23.35 <sup>***</sup> (16.57)	15.65 <sup>***</sup> (12.93)		
	Mean Diff	-9.75 <sup>b,d</sup>	-18.85 <sup>a,c</sup>	-11 <sup>b,d</sup>	-17.4 <sup>a,c</sup>		
	(95% CI)	(-13.37, 6.13)	(-22.56, 12.14)	(-14.98, 7.02)	(-21.07, 13.73)		
	Percentage Change (%)	-43.47 (32.76)	-57.36 (22.24)	-36.56 (20.84)	-61.72 (26.34)		
TBF (flux/min)	Pre	10.13 (3.54)	9.94 (2.88)	10.07 (2.3)	10.41 (3.33)	< 0.001	0.71
	Post	12.17 (3.92)	41.05 <sup>***</sup> (15.95)	14.00 <sup>*</sup> (9.54)	43.44 <sup>***</sup> (13.83)		
	Mean Diff	2.03 <sup>b,d</sup>	31.12 <sup>a,c</sup>	3.93 <sup>b,d</sup>	33.04 <sup>a,c</sup>		
	(95% CI)	(0.52, 0.72)	(23.66, 38.58)	(-0.79, 8.64)	(26.11, 39.96)		
	Percentage Change (%)	24.24 (34.7)	341.99 (208.3)	47.07 (118.34)	368.08 (234.71)		
PPT (kPa)	Pre	416.09 (136.92)	452.75 (183.74)	445.62 (179.35)	457.35 (195.92)	<0.001	0.48
	Post	441.78 <sup>**</sup> (132.44)	562.73 <sup>***</sup> (207.32)	500.97 <sup>***</sup> (185.33)	569.79 <sup>***</sup> (199.41)		
	Mean Diff	25.69 <sup>b,c,d</sup>	109.98 <sup>a,c</sup>	55.35 <sup>a,b,d</sup>	112.44 <sup>a,c</sup>		
	(95% CI)	(8.25, 43.13)	(92.54, 127.42)	(37.91, 72.79)	(95, 129.88)		
	Percentage Change (%)	9.51 (18.17)	26.73 (11.78)	14.13 (15.41)	28.92 (13.57)		
CPT (°C)	Pre	2.4 (3.03)	3.15 (2.6)	1.97 (2.46)	2.97 (3.1)	< 0.001	0.24
	Post	2.12 (2.78)	1.0 <sup>***</sup> (1.42)	1.19 <sup>*</sup> (2.06)	0.7 <sup>***</sup> (1.4)		
	Mean Diff	-0.28 <sup>b,d</sup>	-2.16 <sup>a,c</sup>	-0.78 <sup>b,d</sup>	-2.27 <sup>a,c</sup>		
	(95% CI)	(-0.43, 0.98)	(-2.87, -1.45)	(-1.49, 0.08)	(-2.98, -1.56)		
	Percentage Change (%)						

	Percentage Change (%)	-13.57 (30.09)	-66.08 (36.03)	-36.19 (41.8)	-62.19 (38.35)			
HPT (°C)	Pre	43.49 (3.46)	43.91 (2.8)	45.16 (2.83)	44.35 (3.43)	<0.001	0.59	
	Post	43.72 (3.36)	47.76 *** (2.03)	45.02 (3.02)	47.06 *** (2.51)			
	Mean Diff (95% CI)	0.23 <sup>b,d</sup> (-0.4, 0.87)	3.85 <sup>a,c,d</sup> (3.21, 4.48)	-0.14 <sup>b,d</sup> (-0.78, 0.49)	2.71 <sup>a,b,c</sup> (2.08, 3.35)			
	Percentage Change (%)	0.57 (2.21)	8.96 (4.34)	-0.34 (2.87)	6.34 (3.72)			
	TrA thickness (mm)	Pre	2.6 (0.71)	2.59 (0.48)	2.43 (0.44)	2.54 (0.47)	<0.001	0.76
	Post	2.62 (0.75)	2.6 (0.44)	3.05 *** (0.55)	3.23 *** (0.58)			
Mean Diff (95% CI)	0.02 <sup>c,d</sup> (-0.6, 0.11)	0.003 <sup>c,d</sup> (-0.08, 0.09)	0.63 <sup>a,b</sup> (0.54, 0.71)	0.69 <sup>a,b</sup> (0.61, 0.77)				
Percentage Change (%)	0.81 (5.76)	0.64 (7.01)	25.58 (7.26)	27.58 (9.97)				
LPS (level)	Pre	1.95 (0.39)	2.15 (0.37)	2.05 (0.39)	1.75 (0.44)	<0.001	0.4	
	Post	1.95 (0.39)	2.15 (0.37)	2.45 *** (0.51)	2.4 *** (0.5)			
	Mean Diff (95% CI)	0 <sup>c,d</sup> (0, 0)	0 <sup>c,d</sup> (0, 0)	0.4 <sup>a,b,d</sup> (0.16, 0.64)	0.65 <sup>a,b,c</sup> (0.42, 0.88)			
	Percentage Change (%)	0	0	22.5 (30.24)	45.0 (39.4)			

469 No significant differences in the baseline data among 4 conditions ( $p > 0.05$ )

470 Significant differences between pre-post (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ )

471 <sup>a</sup> Significant difference between control ( $p < 0.05$ )

472 <sup>b</sup> Significant differences between LS+HP ( $p < 0.05$ )

473 <sup>c</sup> Significant differences between LS+CSE ( $p < 0.05$ )

474 <sup>d</sup> Significant differences between LS+HP+CSE ( $p < 0.05$ )

475  $\eta_p^2$  = Partial eta-squared

476 ES = Effect size (Cohen's f score)

477

478

479

480



481

482 **Figure Legends**

483 **Figure 1** CONSORT flow diagram of participant recruitment and allocation in the study

484 **Figure 2.** Ultrasound image of the Transversus abdominis muscle.

485 **Figure 3.** The percentage change for the primary and secondary outcomes. Traditional lumbar  
486 support (TLS): filled column, novel lumbar support with hot pack (NLSD + HP): striped column,  
487 novel lumbar support with biofeedback device (NLSD + BO): dotted column, novel lumbar  
488 support with hot pack and biofeedback device (NLSD + HP with BO: twill column. PI: pain  
489 intensity, TBF: tissue blood flow, PPT: pressure pain threshold, CPT: cold pain threshold, HPT:  
490 heat pain threshold, TrA: thickness of transversus abdominis muscle, LPST: lumbopelvic stability  
491 test.

492

493

494